A Study to Evaluate ALN-4285 in Adult Healthy Volunteers

Study Summary

The purpose of this study is to: * evaluate the safety and tolerability of single ascending doses of ALN-4285 in healthy volunteers * characterize the single-dose pharmacokinetics (PK) of ALN-4285

Conditions

Healthy Volunteers

Interventions / Drugs

ALN-4285 Placebo

View on ClinicalTrials.gov ↗

Sponsor

ALNY

Alnylam Pharmaceuticals

RNAi Therapeutics

F28/100

Study Details

Enrollment76 participants

Primary Completion—

Lead SponsorAlnylam Pharmaceuticals

Data Retrieved2026-04-11 02:53:26.219313+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.